At-home Leqembi does not reduce MRI monitoring for ARIA in 2026. Medscape reports people with mild cognitive impairment still need a baseline brain MRI plus scans after about 1, 2, 3 and 6 months.
Leqembi is lecanemab, an anti-amyloid drug for mild cognitive impairment or mild dementia due to Alzheimer's. ARIA means amyloid-related imaging abnormalities, including brain swelling or fluid and small bleeds seen on MRI. Home dosing changes where shots happen, not how closely the brain is watched.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Does home dosing change MRI timing?
- What is ARIA and why do early weeks matter?
- Does ApoE epsilon 4 status change your risk questions?
- What backup should you confirm before first home dose?
Does home dosing change MRI timing?
Eisai and BioArctic said in their July 13, 2026 press release that FDA approved a 500-mg weekly subcutaneous starting dose. The dose uses two 250-mg autoinjector shots of about 15 seconds for adults with mild cognitive impairment or mild dementia due to Alzheimer's. The companies said launch was planned for late August 2026. The same companies said patients can use IV or subcutaneous Leqembi for the full course from start through maintenance.
Patients can also switch routes as needed. That replaced the prior requirement for 18 months of IV first. Medscape reported in its August 28, 2026 home-lecanemab review that labeling still requires baseline and follow-up MRIs after about 1, 2, 3 and 6 months. The schedule applies whether lecanemab is given IV or subcutaneously. The Alzheimer's Drug Discovery Foundation called the action the first allowing Alzheimer's anti-amyloid treatment to begin with at-home administration.
What is ARIA and why do early weeks matter?
ARIA-E is brain swelling or fluid seen on MRI. An FDA safety communication said FDA added an earlier MRI before the third IV infusion on August 28, 2025. The added scan was meant to detect ARIA-E sooner, along with baseline and pre-5th, 7th and 14th infusion scans. Treatment requires confirmed amyloid-beta pathology and early-stage disease.
An FDA approval announcement said baseline MRI plus vigilance during the first 14 weeks help exclude high-bleed-risk findings. Those findings include multiple microhemorrhages or siderosis. Early symptoms can be subtle, so timing matters more than location of dosing. Ask whether your center reads surveillance MRIs urgently, even when injections happen at home. Ask how a missed or delayed scan affects the next dose.
Does ApoE epsilon 4 status change your risk questions?
Eisai prescribing information summarized in a March 2026 Biogen filing report says ApoE epsilon 4 homozygotes face markedly higher ARIA risk on lecanemab. Symptomatic ARIA-E occurred in 9% of homozygotes, versus 2% in heterozygotes and 1% in noncarriers. Homozygotes make up about 15% of Alzheimer's patients, so testing is recommended before starting. That result does not by itself decide treatment.
It changes counseling, consent, and threshold for urgent imaging. Ask when testing will be done and who will explain the result. Ask whether homozygote status changes MRI frequency, phone triage, or dose-hold rules at your center. Ask how heterozygote and noncarrier results are handled differently, if at all.
What backup should you confirm before first home dose?
Medscape experts stress at-home lecanemab still needs caregiver training and clinician oversight. Prompt evaluation remains essential for new neurologic symptoms.
Ask how urgent MRIs and dose holds are handled nights and weekends. Ask for a written plan covering these warning signs: Bring a list of blood thinners, prior bleeds, and prior abnormal brain MRIs to the visit. Ask who orders the urgent scan, where it is done, and how dosing pauses until results return.
- new or worsening headache
- confusion, dizziness, or trouble thinking clearly
- vision changes
- other sudden neurologic changes
You Might Also Like
- PrecivityAD2 Testing for Symptomatic Adults 40 and Older in 2026: Questions People With Mild Cognitive Impairment Can Bring to a Clinician
- The Long-Term Care Data Cooperative and Dementia Research in 2026: What Is Established and What Remains Uncertain for People With Mild Cognitive Impairment
- Electronic Health Records for Dementia Care Research in 2026: What Is Established and What Remains Uncertain for People With Mild Cognitive Impairment
